Exiqon Reaffirms Plan to Pursue miRNA Dx Only Through Partnerships, Provides Few Details on Programs | GenomeWeb

By Doug Macron

Exiqon last week said that it remains committed to advancing its pipeline of microRNA-based cancer diagnostics to market, and reaffirmed that it would only do so with the help of a partner.

However, the Danish company provided few new details about when deals may be signed or when products would be ready for commercialization.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

In Nature this week: genetic history of HIV in the US, and more.